cycloheptanesulfonic acid | 135469-42-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: cycloheptanesulfonic acid
• 英文别名: Cycloheptanesulfonic acid, AldrichCPR
• CAS: 135469-42-0
• 化学式: C₇H₁₄O₃S
• 分子量: 178.252
• InChiKey: FIUANIHAOGKZPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  环庚烷 在 甲酸 、 二氧化硫 、 氢气 、 双氧水 、 汞 作用下， 生成 cycloheptanesulfonic acid
  参考文献：
  名称：

  Mercury-photosensitized sulfination, hydrosulfination, and carbonylation of hydrocarbons: alkane and alkene conversion to sulfonic acids, ketones, and aldehydes

  摘要：

  Mercury-photosensitized sulfination of alkanes, RH, with SO2 forms sulfinic acids (RSOOH) and sulfinate esters (RSOOR) in high conversion and yield; oxidation of the mixture produces RSO2OH in high yield. Mercury-photosensitized hydrosulfination of alkenes with H2 and SO2 gives RSO2OH after oxidative workup. Mercury-photosensitized carbonylation of alkanes with CO gives RCHO and R2CO.

  DOI：

  10.1021/jo00019a006

文献信息

• [EN] LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME<br/>[FR] LIGANDS DE LA PROTÉINE 2 DE TYPE LANTHIONINE C, CELLULES PRÉPARÉES AVEC CEUX-CI, ET THÉRAPIES LES UTILISANT
  申请人：LANDOS BIOPHARMA INC

  公开号：WO2021127472A1

  公开（公告）日：2021-06-24

  Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including autoimmune diseases, inflammatory diseases, chronic inflammatory diseases, diabetes, and infectious diseases, such as lupus, rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, viral diseases, and nonalcoholic steatohepatitis. The compounds can also be used to generate cells, such as immune cells, for treating the conditions.

  提供的是靶向兰硫氨酸合成酶C样蛋白2途径的化合物。这些化合物可用于治疗多种疾病，包括自身免疫性疾病、炎症性疾病、慢性炎症性疾病、糖尿病和传染性疾病，如狼疮、类风湿性关节炎、1型糖尿病、炎症性肠病、病毒性疾病和非酒精性脂肪肝炎。这些化合物还可用于生成细胞，如免疫细胞，以治疗这些疾病。
• [EN] PLXDC2 LIGANDS<br/>[FR] LIGANDS DE PLXDC2
  申请人：LANDOS BIOPHARMA INC

  公开号：WO2021195360A1

  公开（公告）日：2021-09-30

  Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.

  提供了针对含有plexin结构域2（PLXDC2）的化合物。这些化合物可以用于治疗炎症或免疫介导性疾病、糖尿病、传染病和癌症等疾病。这些化合物可以用于治疗系统性红斑狼疮、类风湿关节炎、多发性硬化症、自身免疫性脑炎、糖尿病肾病、糖尿病视网膜病变、银屑病和炎症性肠病等特定疾病。
• Catalytic composition of organotin compounds
  申请人：Roder Jens

  公开号：US20060047101A1

  公开（公告）日：2006-03-02

  The present invention relates to catalytic compositions for esterification, transestrification and polycondensation reactions, a process for the catalysis of said reactions employing such catalytic compositions and polyesters for resins obtainable by this process.

  本发明涉及用于酯化、转酯化和聚缩反应的催化组合物，使用这种催化组合物进行催化反应的过程以及通过该过程获得的树脂用聚酯。
• Methods and compositions for treating amyloid-related diseases
  申请人：Kong Xianqi

  公开号：US20070010573A1

  公开（公告）日：2007-01-11

  Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

  描述了用于治疗或预防与淀粉样蛋白相关的疾病的方法、化合物、制药组合物和试剂盒。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF
  申请人：NAKAI Hisao

  公开号：US20100063104A1

  公开（公告）日：2010-03-11

  It is intended to provide a compound represented by the formula (I): wherein all the symbols are as defined in the description; which has a p38 MAP kinase inhibitory activity, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. The compound of the invention is useful for preventing or treating a disease in which the abnormal production of a cytokine such as an inflammatory cytokine or a chemokine or overreaction to them is considered to be involved in the cause and aggravation of pathological conditions, in other words, an inflammatory disease, a respiratory disease, a cardiovascular disease, a central nervous system disease or the like, which is a cytokine-mediated disease.

  本发明旨在提供一种由公式（I）表示的化合物：其中所有符号如描述中所定义的；其具有p38 MAP激酶抑制活性，其盐，其N-氧化物，其溶剂合物或其前药。本发明的化合物可用于预防或治疗疾病，其中被认为异常产生细胞因子如炎症性细胞因子或趋化因子或对它们过度反应与病理情况的发生和加重有关，换句话说，是细胞因子介导的疾病，例如炎症性疾病，呼吸系统疾病，心血管疾病，中枢神经系统疾病或类似疾病。